We can’t show the full text here under this license.
Safety and effectiveness of weekly semaglutide compared to daily sitagliptin alone in Japanese people with type 2 diabetes
Updated
Abstract
Overall, 308 participants were randomized and exposed to treatment with semaglutide or sitagliptin.
- The discontinuation rate due to adverse events was higher in the semaglutide 1.0 mg group (14.7%) compared to both the semaglutide 0.5 mg and sitagliptin groups (2.9%).
- Treatment-emergent adverse events were reported more frequently in participants treated with semaglutide (74.8% for 0.5 mg and 71.6% for 1.0 mg) compared to sitagliptin (66.0%).
- Most adverse events associated with semaglutide were mild to moderate, with gastrointestinal issues being the most common.
- Mean glycated hemoglobin (HbA1c) decreased significantly with semaglutide (1.9% for 0.5 mg and 2.2% for 1.0 mg) compared to sitagliptin (0.7%).
- Body weight was reduced by 2.2 kg with semaglutide 0.5 mg and 3.9 kg with 1.0 mg, compared to no significant change with sitagliptin.
Simplified
Key numbers
1.9%
Decrease in HbA1c
Change from baseline after 30 weeks of treatment
3.9 kg
Body weight reduction
Change from baseline after 30 weeks of treatment with semaglutide 1.0 mg
74.8%
Treatment-emergent adverse events
Proportion of participants reporting TEAEs with semaglutide 0.5 mg